Clinical Trials
25 trialsALA /NSCLC
Ain Shams University
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
HYPERBOLIC
Università Vita-Salute San Raffaele
REBIMMUNE
Assistance Publique - Hôpitaux de Paris
Nezha
Second Xiangya Hospital of Central South University
REALM-Post
Shanghai Chest Hospital
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
Second Xiangya Hospital of Central South University
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
TRANSLATE
Pfizer
PROMISE
Centre hospitalier de l'Université de Montréal (CHUM)
MESOVAX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer
Casa Sollievo della Sofferenza IRCCS
The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action
Kaohsiung Medical University Chung-Ho Memorial Hospital
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
University of California, San Francisco
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged
University of Colorado, Denver
Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants
National Taiwan University Hospital
ELY
Hôpital Cochin
Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer
National Taiwan University Hospital
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
TWISTlung
European Georges Pompidou Hospital
Autologous Redirected RNA Meso-CIR T Cells
University of Pennsylvania
HX4 in SCLC
Maastricht Radiation Oncology